Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.